Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a ...

Takeda is organized around five core businesses: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for over 80% of revenue. It also has a developing ...

Data Synthesis: Cilomilast is a second-generation PDE4 inhibitor with antiinflammatory ... cilomilast improved ~3.6 points vs placebo worsened ~0.5 points (p < 0.001) pts. exacerbation-free ...

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney ...

Timeline and planning for New Drug Application submissions remain on track ...

Additional safety signals have been identified with apremilast, with some adverse events specific to certain patient populations.

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver ...

an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma ...

Omeros Corporation ("Omeros" or the "Company") today announced that it has entered into exchange agreements (the "Exchange Agreements") with a limited number of investors who are holders of the ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat ... to predict that Dupixent could see sales of $3.5 billion from that indication alone.